Want to join the conversation?
Specialty biopharmaceutical company $MNK said it has diversified its hospital growth portfolio by acquiring three commercial-stage, global specialty hemostasis brands from $MDCO for an initial payment of approx. $175MM, inclusive of existing inventory. $MNK will invest in market development of RECOTHROM, PreveLeak and RAPLIXA.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.